Valuation dashboard for Citius Pharmaceuticals, Inc. (CTXR) with P/E N/A, P/B 0.21, EV/EBITDA 0.06 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
Analysis Summary
Trailing-twelve-month margins: gross margin 20.0%, operating margin -8.6%, net margin -6.5%.
At the current price of $0.56, CTXR has negative trailing earnings (P/E not meaningful) and an ROE of -67.15%. Market capitalisation stands at $6M.
Balance sheet quality for CTXR: current ratio of 0.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.21 |
| EV / EBITDA | 0.06 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.92 |
| vs Current Price | +64.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CTXR | Citius Pharmaceuticals, Inc. | $6M | 0.21 | -67.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.56 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -67.15% |
| Return on Invested Capital | -67.62% |
| Return on Assets | -32.53% |
| Gross Margin | 19.97% |
| Operating Margin | -863.92% |
| Net Margin | -651.27% |
Related companies: ADTX · APLM · ATHA · CRIS · DARE · FBLG · ICU
Explore sector: Healthcare · Biotechnology
More sections of CTXR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks